Ascentage Pharma Group International (AAPG) is trading down at $14.75 (-4.00%), as of the latest quote. It operates in the Health Care sector.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | |
|---|---|---|---|
| Income statement | |||
| Revenue | CN¥209.7M | CN¥222.0M | CN¥980.6M |
| Growth (year over year) | — | +5.9% | +341.8% |
| Gross profit | CN¥187.7M | CN¥191.4M | CN¥951.6M |
| Gross margin | 89.5% | 86.2% | 97.0% |
| Net income | −CN¥882.9M | −CN¥925.6M | −CN¥405.4M |
| Net margin | −421.0% | −417.0% | −41.3% |
| EPS (diluted) | −CN¥3.35 | −CN¥3.28 | −CN¥1.34 |
| Balance sheet | |||
| Cash and equivalents | CN¥1.35B | CN¥1.04B | CN¥893.1M |
| Total liabilities | — | CN¥2.43B | CN¥2.34B |
| Shareholders' equity | CN¥408.7M | CN¥60.4M | CN¥264.2M |
| Cash flow | |||
| Operating cash flow | −CN¥653.9M | −CN¥726.1M | −CN¥111.4M |
| Capital expenditure | CN¥203.3M | CN¥46.1M | CN¥24.3M |
| Free cash flow | −CN¥857.2M | −CN¥772.2M | −CN¥135.6M |
| Share buybacks | CN¥26.8M | CN¥5.92M | — |
From Ascentage Pharma Group International's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Chinese Yuan (CNY), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Ascentage Pharma Group International in our feed yet.